Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 441-443

  Liu, Jiang Wen ^a   Liu, Dan ^a   Cui, Ke Zhen ^a   Xu, Ying ^a   Li, Yan Bo ^a   Sun, Yan Ming ^a   Su, Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetic cardiomyopathy; Free fatty acid; Hyperglycemia; Oxidative stress; Protein kinase C

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOTHELIN 1; FATTY ACID; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYOL; PROTEIN KINASE C; SOMATOMEDIN C RECEPTOR; SORBITOL;

DIABETIC CARDIOMYOPATHY; FATTY ACID METABOLISM; GLYCOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; MOLECULAR MECHANICS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION;

DIABETIC CARDIOMYOPATHIES; ENZYME ACTIVATION; FATTY ACIDS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; POLYMERS; PROTEIN KINASE C;

EID: 84867866085     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.058     Document Type: Short Survey

References (48)

1. Cao Z., Cooper M.E. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetol. 2012, 49:243-254.
2. Garcia-Touza M., Sowers J.R. Evidence-based hypertension treatment in patients with diabetes. J. Clin. Hypertens. 2012, 14:97-102.
3. Acar E., Ural D., Bildirici U., Sahin T., Yilmaz I. Diabetic cardiomyopathy. Anadolu Kardiyol. Der. 2011, 11:732-737.
4. Seferovic Mitrovic J.P., Seferovic P.M., Vujisic Tesic B., Petrovic M., Ristic A.D., Lalic K., Jotic A., Tesic M., Giga V., Milic N., Singh S., Lalic NM. Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes. Int. J. Cardiol. 2012, 156:219-221.
5. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
6. Murarka S., Movahed M.R. Diabetic cardiomyopathy. J. Card. Fail. 2010, 16:971-979.
7. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect. 2002, 15:197-205.
8. Aneja A., Tang W.H., Bansilal S., Garcia M.J., Farkouh M.E. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med. 2008, 121:748-757.
9. Chen S., Evans T., Mukherjee K., Karmazyn M., Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J. Mol. Cell. Cardiol. 2000, 32:1621-1629.
10. Frustaci A., Kajstura J., Chimenti C., Jakoniuk I., Leri A., Maseri A., et al. Myocardial cell death in human diabetes. Circ. Res. 2000, 87:1123-1132.
11. Yoshimura M., Anzawa R., Mochizuki S. Cardiac metabolism in diabetes mellitus. Curr. Pharm. Des. 2008, 14:2521-2526.
12. Tarquini R., Lazzeri C., Pala L., Rotella C.M., Gensini G.F. The diabetic cardiomyopathy. Acta Diabetol. 2011, 48:173-181.
13. Mizushige K., Yao L., Noma T., Kiyomoto H., Yu Y., Hosomi N., et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000, 101:899-907.
14. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 2003, 112:1049-1057.
15. Susic D., Varagic J., Ahn J., Frohlich E.D. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4:97-101.
16. Zieman S.J., Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004, 64:459-470.
17. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., Okuda S., Imaizumi T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2007, 40:10-15.
18. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr. Diab. Rep. 2011, 11:244-252.
19. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther. Apher. Dial. 2009, 13:534-539.
20. Xiang H., McNeill J.H. Protein kinase C activity is altered in diabetic rat hearts. Biochem. Biophys. Res. Commun. 1992, 187:703-710.
21. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
22. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., King G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Nat. Acad. Sci. USA 1992, 89:11059-11063.
23. Meier M., King G.L. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc. Med. 2000, 5:173-185.
24. Rodrigues B., Cam M.C., McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol. Cell. Biochem. 1998, 180:53-57.
25. Nakayama H., Morozumi T., Nanto S., Shimonagata T., Ohara T., Takano Y., Kotani J., Watanabe T., Fujita M., Nishio M., Kusuoka H., Hori M., Nagata S. Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn. Circ. J. 2001, 65:783-787.
26. Malone J.I., Schocken D.D., Morrison A.D., Gilbert-Barness E. Diabetic cardiomyopathy and carnitine deficiency. J. Diabetes Complications 1999, 13:86-90.
27. Hickson-Bick D.L., Buja M.L., McMillin J.B. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J. Mol. Cell. Cardiol. 2000, 32:511-519.
28. Szczepaniak L.S., Victor R.G., Orci L., Unger R.H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 2007, 101:759-767.
29. Khavandi K., Khavandi A., Asghar O., Greenstein A., Withers S., Heagerty A.M., Malik R.A. Diabetic cardiomyopathy- a distinct disease?. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:347-360.
30. Hayat S.A., Patel B., Khattar R.S., Malik R.A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. (Lond.) 2004, 107:539-557.
31. Abe T., Ohga Y., Tabayashi N., Kobayashi S., Sakata S., Misawa H., Tsuji T., Kohzuki H., Suga H., Taniguchi S., Takaki M. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:138-148.
32. Cohen-Solal A., Beauvais F., Loqeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J. Card. Fail. 2008, 14:615-625.
33. Wilson J.M., Villareal R.P., Hariharan R., Massumi A., Muthupillai R., Flamm S.D. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex. Heart Inst. J. 2002, 29:176-180.
34. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res. 1989, 65:657-670.
35. Gabbay K.H. The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 1973, 288:831-836.
36. Cameron N.E., Cotter M.A. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992, 35:1011-1019.
37. Obrosova I.G., Kador P.F. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12:373-385.
38. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42:801-813.
39. Sano T., Umeda F., Hashimoto T., Nawata H., Utsumi H. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 1998, 41:1355-1360.
40. Inoguchi T., Sonta T., Tsubouchi H., Etoh T., Kakimoto M., Sonoda N., Sato N., Sekiguchi N., Kobayashi K., Sumimoto H., Utsumi H., Nawata H. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J. Am. Soc. Nephrol. 2003, 14:S227-S232.
41. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004, 25:543-567.
42. Li X., Xu Z., Li S., Rozanski G.J. Redox regulation of Ito remodeling in diabetic rat heart. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1417-H1424.
43. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
44. Chiu J., Farhangkhoee H., Xu B.Y., Chen S., George B., Chakrabarti S. PARP mediates structural alterations in diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 2008, 45:385-393.
45. Zheng L., Kern T.S. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front. Biosci. 2009, 14:3974-3987.
46. Pieper A.A., Brat D.J., Krug D.K., Watkins C.C., Gupta A., Blackshaw S., Verma A., Wang Z.Q., Snyder S.H. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc. Nat. Acad. Sci. USA 1999, 96:3059-3064.
47. Yang Z., Zingarelli B., Szabo C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 2000, 13:60-66.
48. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 2003, 112:1049-1057.